MA1-80527

antibody from Invitrogen Antibodies

Targeting: JCHAIN IGCJ, IGJ, JCH

Western blot (Recommended by provider)

ELISA (Recommended by provider)

Immunoprecipitation (Recommended by provider)

Immunohistochemistry (Recommended by provider)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

MA1-80527

Provider

Invitrogen Antibodies

Product name

J Chain Monoclonal Antibody (Mc19-9)

Antibody type

Monoclonal

Antigen

Other

Description

This antibody does not detect J chain in intact IgM in ELISA Assays due to steric hindrance. In Western Blotting techniques MA1-80527 detects J chain in IgM only under reducing conditions. Mouse anti Human J chain antibody, clone Mc19-9 reacts with human J chain as tested by ELISA using purified human Ig fragments as the solid phase target antigen.

Reactivity

Human

Host

Mouse

Isotype

IgG

Antibody clone number

Mc19-9

Vial size

200 µg

Concentration

1 mg/mL

Storage

Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

References

Submitted references

Transformation strategies for stable expression of complex hetero-multimeric proteins like secretory immunoglobulin A in plants.

Palaci J, Virdi V, Depicker A
Plant biotechnology journal 2019 Sep;17(9):1760-1769

---

Increased Cathepsin S activity associated with decreased protease inhibitory capacity contributes to altered tear proteins in Sjögren's Syndrome patients.

Edman MC, Janga SR, Meng Z, Bechtold M, Chen AF, Kim C, Naman L, Sarma A, Teekappanavar N, Kim AY, Madrigal S, Singh S, Ortiz E, Christianakis S, Arkfeld DG, Mack WJ, Heur M, Stohl W, Hamm-Alvarez SF
Scientific reports 2018 Jul 23;8(1):11044

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Figure 2 Degradation of LF, Cys C, and sIgA by CTSS occurs in tears from SS patients but not in tears from healthy controls. Tears obtained from SS patients and healthy controls were collected on Schirmer's strips and were eluted in CTSS sample buffer. For LF degradation, tear samples were supplemented with 2.6 ug of recombinant LF only. For Cys C degradation, tear samples were supplemented with 2.5 ug Cys C and 2.6 ug LF. For sIgA degradation, tear samples were supplemented with 5 ug of purified sIgA. All supplemented tear samples were treated without or with recombinant CTSS equivalent to 18,000 RFU/10 mg tear protein for 4 hr at 37 degC. Equal amounts of recombinant LF, Cys C, and purified sIgA in PBS were used as controls. LF ( A ) and Cys C ( B ) loss by degradation was evaluated by Western blotting and densitometry as shown for LF in ( C ) and Cys C in ( D ). sIgA was blotted with both anti J-chain antibody ( E ) to detect multimeric IgA forms and with anti-IgA ( F ) antibody to detect monomeric IgA on the same gel. Densitometry is shown in ( G ) and ( H ), respectively. For quantitation, n = 6 for LF, n = 3 for Cys C and n = 4 for sIgA. Bars show SEM; *p < 0.05, **p < 0.01. Representative blots are shown. Full length blots are shown in Supplementary Figs 2 and 3 .

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Figure 3 Western blot characterization of the selected transformants for each transformation strategy. Detection of SC (a and d), J-chain (b and e) and VHH -IgA (c and f) in a western blot after reducing (+) and non-reducing (-) PAGE . The main bands, indicated with a number, most likely correspond with SC in different glycosylated forms (1), a postulated dimeric SC (2), the assembled sSIgA complex (3), J-chain (4), a single polypeptide of VHH -IgA (5) and truncated versions thereof (6), assembled simplified mIgA (7) and a truncated version of the mIgA (8).